Sugi Predict

Sugi Predict / Compounds / SCHEMBL6742273

SCHEMBL6742273

SCHEMBL6742273

COc1nc(Cl)ccc1C(=O)O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 2/20 0.66
▸ POLB P06746 1/20 0.66
▸ RAB9A P51151 2/20 0.42
▸ TUBB4A P04350 1/20 0.42
▸ TUBB P07437 1/20 0.42
▸ TUBA3C P0DPH7 1/20 0.42
▸ TUBA1B P68363 1/20 0.42
▸ TUBA4A P68366 1/20 0.42
▸ TUBB4B P68371 1/20 0.42
▸ TUBB3 Q13509 1/20 0.42
▸ TUBB2A Q13885 1/20 0.42
▸ TUBB8 Q3ZCM7 1/20 0.42
▸ TUBA3E Q6PEY2 1/20 0.42
▸ TUBA1A Q71U36 1/20 0.42
▸ TUBA1C Q9BQE3 1/20 0.42
▸ TUBB6 Q9BUF5 1/20 0.42
▸ TUBB2B Q9BVA1 1/20 0.42
▸ TUBB1 Q9H4B7 1/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ GABRP O00591 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30437331 1.00 TDP1 (0.66) TDP1POLBRAB9ATUBB4ATUBB
SCHEMBL20719247 0.85 POLB (0.47) TDP1POLBRAB9ATUBB4ATUBB
SCHEMBL11607437 0.85 POLB (0.47) TDP1POLBRAB9ATUBB4ATUBB
SCHEMBL29361411 0.84 NNMT (0.49) TDP1POLBRAB9ATUBB4ATUBB
SCHEMBL31444462 0.84 TUBB4A (0.55) TDP1POLBRAB9ATUBB4ATUBB
SCHEMBL426830 0.84 TUBB4A (0.55) TDP1POLBRAB9ATUBB4ATUBB
SCHEMBL2527039 0.84 NNMT (0.49) TDP1POLBRAB9ATUBB4ATUBB
SCHEMBL20719057 0.82 TDP1 (0.45) TDP1POLBRAB9ATUBB4ATUBB
SCHEMBL6377769 0.82 MAPT (0.49) TDP1POLBRAB9ANPC1HPGD
SCHEMBL15647036 0.81 RAB9A (0.49) TDP1POLBRAB9ATUBB4ATUBB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112300184-A Preparation method of three-membered ring compound 华东师范大学 2021-02-02 — — CN claimed
WO-2025262297-A1 PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 DARK BLUE THERAPEUTICS LTD (GB) 2025-12-26 — — WO disclosed
US-12448368-B2 Indole compounds as androgen receptor modulators NIDO BIOSCIENCES, INC. (US) 2025-10-21 — — US disclosed
EP-4600247-A2 PD-1/PD-L1 INHIBITORS Gilead Sciences, Inc. (US) 2025-08-13 — — EP disclosed
WO-2025134150-A1 BIPHENYL PYRIDINE RIGID COMPOUNDS WITH POLYCYCLIC HETEROCYCLES USEFUL AS DUAL IMMUNE CHECKPOINT INHIBITORS NATCO PHARMA LIMITED (IN) 2025-06-26 — — WO disclosed
EP-3781556-B1 PD-1/PD-L1 INHIBITORS GILEAD SCIENCES INC (US) 2025-06-18 — — EP disclosed
US-20250122176-A1 INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS NIDO BIOSCIENCES INC (US) 2025-04-17 — — US disclosed
US-20250092021-A9 INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS NIDO BIOSCIENCES, INC. 2025-03-20 — — US disclosed
WO-2024245193-A1 HETEROAROMATIC RING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF 上海艾力斯医药科技股份有限公司 2024-12-05 — — WO disclosed
CN-117106056-A Targeting SSTR somatostatin analogue, molecular probe and application thereof 南京江原安迪科正电子研究发展有限公司 2023-11-24 — — CN disclosed
EP-2819519-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC Therapeutics, Inc. (US) 2015-01-07 — — EP disclosed
WO-2013130689-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS, INC. (US) 2013-09-06 — — WO disclosed
WO-2013130689-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS, INC. (US) 2013-09-06 — — WO disclosed
WO-2012110860-A1 TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS GLENMARK PHARMACEUTICALS S.A. (CH) 2012-08-23 — — WO disclosed
WO-2012110860-A1 TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS GLENMARK PHARMACEUTICALS S.A. (CH) 2012-08-23 — — WO disclosed
US-20040127477-A1 Heterocyclic glycyl beta-alanine derivatives G. D. SEARLE & CO. (US) 2004-07-01 — — US disclosed
US-6689754-B1 PIPERIDINE OR PYRIDINE DERIVATIVES; ALPHA V BETA 3 INTEGRIN ANTAGONISTS G. D. SEARLE & CO. 2004-02-10 — — US disclosed
EP-1070060-A1 HETEROCYCLIC GLYCYL BETA-ALANINE DERIVATIVES AS VITRONECTIN ANTAGONISTS G.D. Searle & Co. (US) 2001-01-24 — — EP disclosed
WO-1999052896-A1 HETEROCYCLIC GLYCYL BETA-ALANINE DERIVATIVES AS VITRONECTIN ANTAGONISTS G.D. SEARLE & CO. (US) 1999-10-21 — — WO disclosed
US-4089960-A Antiemetic, psychosomatic and antipsychotic heterocyclic pyridine carboxamides CIBA-GEIGY CORPORATION (US) 1978-05-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040127477-A1 Heterocyclic glycyl beta-alanine derivatives ITGB3, ITGAL, ITGB1 TDP1 3916/4885POLB 4282/4885RAB9A 471/4885
US-20250122176-A1 INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS AR, FSHR, NR5A1 TDP1 1621/4885POLB 1917/4885RAB9A 2811/4885
US-20250092021-A9 INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS AR, FSHR, NR5A1 TDP1 1621/4885POLB 1917/4885RAB9A 2811/4885
US-12448368-B2 Indole compounds as androgen receptor modulators AR, FSHR, ADRB3 TDP1 1371/4885POLB 2183/4885RAB9A 2744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.